- Generic name
- Tofacitinib
- Strength
- 11 mg
- Dosage form
- Xr Tablet
- Manufactured by
- The ACME Laboratories Ltd.
INJAK XR TABLET Xr Tablet
About INJAK XR TABLET 11 mg
INJAK XR TABLET is a xr tablet from The ACME Laboratories Ltd., with the generic name Tofacitinib. INJAK XR TABLET xr tablet is used for adults with moderately to severely active rheumatoid arthritis who have not responded well to or cannot tolerate methotrexate.
There are 13 brands of Tofacitinib listed in Bangladesh. The lowest listed price is Tofacit 5 mg Tablet at ৳ 30.00 per unit.
What is INJAK XR TABLET 11 mg?
INJAK XR TABLET is a xr tablet from The ACME Laboratories Ltd., with the generic name Tofacitinib. It may be given alone or together with methotrexate or other nonbiologic disease-modifying antirheumatic drugs. It is used in adults with rheumatoid arthritis who have not responded well to or cannot tolerate methotrexate. The dose and course are decided by the doctor.
Uses of INJAK XR TABLET
INJAK XR TABLET xr tablet is used for adults with moderately to severely active rheumatoid arthritis who have not responded well to or cannot tolerate methotrexate. It can be taken on its own or alongside methotrexate or other nonbiologic disease-modifying antirheumatic drugs. Your doctor will determine if this medicine is appropriate for your condition.
How to use INJAK XR TABLET
Keep all appointments for check-ups and tests your doctor advises. INJAK XR TABLET is taken by mouth. Swallow the xr tablet with water. If a dose is missed, ask the doctor or pharmacist what to do. Do not change the dose or stop treatment on your own. The dose and course are decided by your doctor based on your condition and other medicines you take.
Side effects of INJAK XR TABLET
Common side effects reported during the first three months of treatment include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis. Because this medicine affects the immune system, serious infections can occur. Ask the doctor or pharmacist about anything you notice. Tell your doctor promptly about fever, persistent cough, or any sign of infection. Ask your doctor or pharmacist about what to watch for.
Safety and precautions
It may increase the risk of infections and gastrointestinal perforations. Ask the doctor first if you have kidney or liver problems, take other medicines, or are pregnant, planning pregnancy or breastfeeding. It should be used with caution in people at increased risk of gastrointestinal perforation. Tell your doctor about all your medical conditions and medicines before starting.
Frequently asked questions
What does INJAK XR TABLET treat?
INJAK XR TABLET xr tablet is used for adults with moderately to severely active rheumatoid arthritis who have not responded well to or cannot tolerate methotrexate. It can be taken on its own or alongside methotrexate or other nonbiologic disease-modifying antirheumatic drugs.
How is INJAK XR TABLET used?
Keep all appointments for check-ups and tests your doctor advises. INJAK XR TABLET is taken by mouth.
Can INJAK XR TABLET cause side effects?
Common side effects reported during the first three months of treatment include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis. Because this medicine affects the immune system, serious infections can occur.
Who should be careful with INJAK XR TABLET?
It may increase the risk of infections and gastrointestinal perforations. Ask the doctor first if you have kidney or liver problems, take other medicines, or are pregnant, planning pregnancy or breastfeeding.
Indications
Psoriatic Arthritis: Tofacitinib is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Ulcerative Colitis: Tofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
Pharmacology
Tofacitinib is a partial and reversible janus kinase (JAK) inihibitor that will prevent the body from responding to cytokine signals. By inhibiting JAKs, tofacitinib prevents the phosphorylation and activation of STATs. The JAK-STAT signalling pathway is involved in the transcription of cells involved in hematopoiesis, and immune cell function. Tofacitinib works therapeutically by inhibiting the JAK-STAT pathway to decrease the inflammatory response. However, there is evidence to suggest that it may also achieve efficacy via other pathways as well.
Dosage & Administration
Psoriatic Arthritis (in combination with nonbiologic DMARDs): Tofacitinib 5 mg twice daily or Tofacitinib 11 mg once daily. Recommended dosage in patients with moderate and severe renal impairment or moderate hepatic impairment is Tofacitinib 5 mg once daily.
Ulcerative Colitis: Tofacitinib 10 mg twice daily for at least 8 weeks; then 5 or 10 mg twice daily. Discontinue after 16 weeks of 10 mg twice daily, if adequate therapeutic benefit is not achieved. Use the lowest effective dose to maintain response.
Interaction
- Potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., Ketoconazole)
- Recommended dose is Tofacitinib 5 mg once daily: One or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole)
- Recommended dose is Tofacitinib 5 mg once daily Potent CYP inducers (e.g.Rifampin): May result in loss of or reduced clinical response.
Side Effects
Pregnancy & Lactation
It is not known whether Tofacitinib is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Tofacitinib, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug for the mother
Precautions & Warnings
- Serious Infections: Avoid use of Tofacitinib during an active serious infection, including localized infections.
- Gastrointestinal Perforations: Use with caution in patients that may be at increased risk.
- Laboratory Monitoring: Recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
- Immunizations: Live vaccines: Avoid use with Tofacitinib.
- Do not initiate Tofacitinib if absolute lymphocyte count <500 cells/mm3, an absolute neutrophil count (ANC) <1000 cells/mm3 or hemoglobin <9 gm/dL.
Storage Conditions
Alternative brands of Tofacitinib
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.